[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
We use cookies to improve user experience, and analyze website traffic.

For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html


[TITLE]Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference:
[TEXT]
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10).

Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at both conferences being held in New York (NY). Each session will be webcast live, and available on demand following the events.
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139147/0/en/Telix-to-Present-at-the-Morgan-Stanley-23rd-Annual-Global-Healthcare-Conference-and-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

================================================================================

[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
We use cookies to improve user experience, and analyze website traffic.

For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html


[TITLE]Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference:
[TEXT]
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10).

Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at both conferences being held in New York (NY). Each session will be webcast live, and available on demand following the events.
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139147/0/en/Telix-to-Present-at-the-Morgan-Stanley-23rd-Annual-Global-Healthcare-Conference-and-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

================================================================================

[TITLE]Wellington Management Group LLP Has $12.53 Million Stake in Jazz Pharmaceuticals PLC $JAZZ:
[TEXT]
Wellington Management Group LLP increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 141.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,962 shares of the specialty pharmaceutical company’s stock after buying an additional 59,159 shares during the period. Wellington Management Group LLP owned 0.16% of Jazz Pharmaceuticals worth $12,534,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Elequin Capital LP increased its holdings in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 119 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 161 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Get Jazz Pharmaceuticals alerts:

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares of the company’s stock, valued at $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Trading Down 0.5%

JAZZ stock opened at $124.43 on Thursday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company’s 50-day simple moving average is $113.72 and its 200 day simple moving average is $117.23. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a market capitalization of $7.55 billion, a PE ratio of -18.49, a price-to-earnings-growth ratio of 7.88 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the company posted $5.30 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several research reports. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $165.00 to $162.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.43.

Check Out Our Latest Report on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Stories

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/wellington-management-group-llp-has-12-53-million-stake-in-jazz-pharmaceuticals-plc-jazz/


[TITLE]Raymond James Financial Inc. Acquires 62,719 Shares of Jazz Pharmaceuticals PLC $JAZZ:
[TEXT]
Raymond James Financial Inc. increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 67.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,066 shares of the specialty pharmaceutical company’s stock after purchasing an additional 62,719 shares during the period. Raymond James Financial Inc.’s holdings in Jazz Pharmaceuticals were worth $19,251,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Nuveen LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at $62,362,000. Perpetual Ltd raised its position in shares of Jazz Pharmaceuticals by 60.2% during the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock valued at $118,212,000 after purchasing an additional 357,784 shares during the period. Ameriprise Financial Inc. raised its position in shares of Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock valued at $289,066,000 after purchasing an additional 293,360 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $28,091,000. 89.14% of the stock is currently owned by institutional investors.

Get Jazz Pharmaceuticals alerts:

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares of the company’s stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 4.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $165.00 to $162.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 6th. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 20th. Piper Sandler reaffirmed an “overweight” rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.43.

Check Out Our Latest Report on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $124.43 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market capitalization of $7.55 billion, a P/E ratio of -18.49, a PEG ratio of 7.88 and a beta of 0.34. The firm has a fifty day simple moving average of $113.72 and a two-hundred day simple moving average of $117.23. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the business earned $5.30 earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Further Reading

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/raymond-james-financial-inc-acquires-62719-shares-of-jazz-pharmaceuticals-plc-jazz/


[TITLE]Nuveen LLC Makes New Investment in Terns Pharmaceuticals, Inc. $TERN:
[TEXT]
Nuveen LLC bought a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,405,901 shares of the company’s stock, valued at approximately $3,880,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TERN. Thrive Wealth Management LLC acquired a new position in shares of Terns Pharmaceuticals in the first quarter valued at approximately $29,000. Vontobel Holding Ltd. acquired a new stake in Terns Pharmaceuticals during the 1st quarter worth approximately $39,000. Velan Capital Investment Management LP bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $94,000. Sherbrooke Park Advisers LLC bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $99,000. Finally, Invesco Ltd. grew its holdings in Terns Pharmaceuticals by 13.3% during the 4th quarter. Invesco Ltd. now owns 23,400 shares of the company’s stock worth $130,000 after acquiring an additional 2,753 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors.

Get Terns Pharmaceuticals alerts:

Terns Pharmaceuticals Price Performance

TERN opened at $6.89 on Thursday. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $11.40. The company’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $3.99. The firm has a market capitalization of $602.94 million, a price-to-earnings ratio of -6.63 and a beta of -0.05.

Insider Activity at Terns Pharmaceuticals

Terns Pharmaceuticals ( NASDAQ:TERN Get Free Report ) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

In other news, CEO Amy L. Burroughs purchased 23,314 shares of the stock in a transaction on Wednesday, June 25th. The stock was purchased at an average price of $3.87 per share, for a total transaction of $90,225.18. Following the acquisition, the chief executive officer owned 47,083 shares in the company, valued at $182,211.21. This trade represents a 98.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Gengos purchased 10,000 shares of the stock in a transaction on Friday, June 27th. The shares were purchased at an average price of $3.93 per share, with a total value of $39,300.00. Following the acquisition, the chief financial officer owned 25,000 shares in the company, valued at approximately $98,250. The trade was a 66.67% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 48,314 shares of company stock valued at $186,575. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets reduced their target price on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.63.

View Our Latest Stock Report on Terns Pharmaceuticals

Terns Pharmaceuticals Profile

(Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Featured Stories

Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report).

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/nuveen-llc-makes-new-investment-in-terns-pharmaceuticals-inc-tern/


[TITLE]BI Asset Management Fondsmaeglerselskab A S Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM:
[TEXT]
BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 648 shares of the company’s stock, valued at approximately $34,000.

A number of other large investors also recently added to or reduced their stakes in RYTM. Westfield Capital Management Co. LP acquired a new position in Rhythm Pharmaceuticals during the first quarter worth $71,038,000. Janus Henderson Group PLC boosted its holdings in Rhythm Pharmaceuticals by 103.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock worth $68,309,000 after buying an additional 621,432 shares during the last quarter. Stempoint Capital LP boosted its holdings in Rhythm Pharmaceuticals by 404.1% in the 4th quarter. Stempoint Capital LP now owns 208,016 shares of the company’s stock worth $11,645,000 after buying an additional 166,748 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/27/bi-asset-management-fondsmaeglerselskab-a-s-makes-new-investment-in-rhythm-pharmaceuticals-inc-rytm/

================================================================================

[TITLE]Hsbc Holdings PLC Purchases 2,669 Shares of Medpace Holdings, Inc. $MEDP:
[TEXT]
Hsbc Holdings PLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 157.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,364 shares of the company’s stock after acquiring an additional 2,669 shares during the quarter. Hsbc Holdings PLC’s holdings in Medpace were worth $1,296,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. lifted its holdings in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares during the period. Colonial Trust Co SC lifted its holdings in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company’s stock valued at $58,000 after acquiring an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Medpace in the first quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/30/hsbc-holdings-plc-purchases-2669-shares-of-medpace-holdings-inc-medp/


[TITLE]American Century Companies Inc. Increases Holdings in Ligand Pharmaceuticals Incorporated $LGND:
[TEXT]
American Century Companies Inc. grew its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 8.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,456 shares of the biotechnology company’s stock after buying an additional 3,219 shares during the period. American Century Companies Inc.’s holdings in Ligand Pharmaceuticals were worth $4,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. Aberdeen Group plc lifted its holdings in Ligand Pharmaceuticals by 22.3% during the 1st quarter. Aberdeen Group plc now owns 216,241 shares of the biotechnology company’s stock worth $22,736,000 after buying an additional 39,481 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in Ligand Pharmaceuticals by 16.5% during the 1st quarter. Cookson Peirce & Co. Inc. now owns 8,915 shares of the biotechnology company’s stock worth $937,000 after buying an additional 1,265 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Ligand Pharmaceuticals by 41.6% during the 1st quarter. Russell Investments Group Ltd. now owns 135,365 shares of the biotechnology company’s stock worth $14,232,000 after buying an additional 39,765 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in Ligand Pharmaceuticals by 27.1% during the 1st quarter. Public Sector Pension Investment Board now owns 59,878 shares of the biotechnology company’s stock worth $6,296,000 after buying an additional 12,783 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Ligand Pharmaceuticals during the 1st quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/30/american-century-companies-inc-increases-holdings-in-ligand-pharmaceuticals-incorporated-lgnd/


[TITLE]Quantbot Technologies LP Acquires 136 Shares of argenex SE $ARGX:
[TEXT]
Quantbot Technologies LP raised its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 4,533.3% in the 1st quarter, Holdings Channel reports. The firm owned 139 shares of the company’s stock after purchasing an additional 136 shares during the quarter. Quantbot Technologies LP’s holdings in argenex were worth $82,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. RTW Investments LP increased its stake in shares of argenex by 2.9% during the fourth quarter. RTW Investments LP now owns 673,497 shares of the company’s stock valued at $414,201,000 after buying an additional 19,067 shares during the period. Lord Abbett & CO. LLC increased its stake in shares of argenex by 33.2% during the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock valued at $162,585,000 after buying an additional 68,498 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of argenex by 22.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 176,450 shares of the company’s stock valued at $100,063,000 after buying an additional 32,239 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of argenex during the fourth quarter valued at $91,013,000. Finally, GAMMA Investing LLC increased its stake in shares of argenex by 53,684.9% during the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company’s stock valued at $802,200,000 after buying an additional 135,286 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Get argenex alerts:

argenex Stock Up 1.2%

argenex stock opened at $712.20 on Friday. argenex SE has a 52 week low of $510.05 and a 52 week high of $716.62. The company has a market capitalization of $43.59 billion, a price-to-earnings ratio of 36.52, a price-to-earnings-growth ratio of 0.81 and a beta of 0.39. The stock has a 50-day moving average price of $611.18 and a 200 day moving average price of $599.83.

Wall Street Analyst Weigh In

argenex ( NASDAQ:ARGX Get Free Report ) last released its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. Research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

Several equities analysts have issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $800.00 target price on shares of argenex in a research note on Monday, August 25th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, July 8th. HC Wainwright lifted their price objective on shares of argenex from $720.00 to $774.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Guggenheim lifted their price objective on shares of argenex from $1,060.00 to $1,070.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, Baird R W raised shares of argenex from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and twenty have assigned a Buy rating to the company. Based on data from MarketBeat.com, argenex presently has a consensus rating of “Buy” and a consensus price target of $766.50.

View Our Latest Report on ARGX

About argenex

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Featured Articles

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/30/quantbot-technologies-lp-acquires-136-shares-of-argenex-se-argx/


[TITLE]Deutsche Bank AG Buys 2,512 Shares of Arcturus Therapeutics Holdings Inc. $ARCT:
[TEXT]
Deutsche Bank AG raised its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 10.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,280 shares of the biotechnology company’s stock after acquiring an additional 2,512 shares during the quarter. Deutsche Bank AG’s holdings in Arcturus Therapeutics were worth $289,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Arcturus Therapeutics by 3.8% in the first quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock worth $18,521,000 after acquiring an additional 64,367 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in shares of Arcturus Therapeutics in the first quarter worth
[Source link]: https://www.etfdailynews.com/2025/08/30/deutsche-bank-ag-buys-2512-shares-of-arcturus-therapeutics-holdings-inc-arct/

================================================================================

[TITLE]Japan Generic Drug Market Trends, Opportunity and Forecast 2025-2033 - Favorable Policies, Rising Healthcare Costs, and Growing Acceptance of Generics Drive Expansion:
[TEXT]
Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The "Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033" has been added to ResearchAndMarkets.com's offering.

The Japan generic drug market is poised for significant growth, with its market size projected to climb from USD 12.3 billion in 2024 to USD 22.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.55% during 2025-2033. This expansion is driven by favorable government policies, increasing healthcare costs, and a growing acceptance of generics among healthcare providers and patients.

Growing Government Policies and Initiatives: The Japanese government actively endorses the use of generics to curb healthcare costs. Incentives, favorable regulations, and public campaigns are key strategies in promoting generics, an integral part of the national healthcare plan. According to a 2024 article by Japan Times, the health ministry is advocating for smaller drugmakers to merge with larger counterparts, ensuring a stable supply amid shortages, thus stimulating market growth.

Increasing Aging Population: Japan's aging demographic significantly boosts the demand for affordable medications. With one of the world's oldest populations, as recognized by the UN, the percentage of citizens aged 65 and older is projected to reach nearly 35% by 2040. This demographic shift fuels demand for cost-effective generics, positioning the market for further expansion.

Rising Healthcare Costs: As healthcare costs rise, patients and providers look to generics for more economical treatment options. Japan's healthcare expenses are predicted to hit approximately 445 billion dollars by 2040. Generics, comprising 80% of prescribed drugs, are anticipated to rise as a strategic measure to manage these costs, according to Meiji.

Report Coverage: The market report offers thorough insights into the generic drug sector in Japan, examining value and volume trends, the COVID-19 impact, and projections through 2033.

Competitive Landscape: Key players leverage government incentives and a favorable regulatory framework to expand their portfolios. The aging populace and increasing healthcare costs drive demand for generic medications, with technological advancements in manufacturing ensuring high-quality production and market competitiveness.

Japan Generic Drug Market Analysis:

Major Market Drivers: Key drivers include proactive government policies that aim to reduce healthcare expenditures by promoting generic drug use. Incentives and favorable regulations make generics a cost-effective alternative to branded medications. The escalating healthcare costs further bolster the market in Japan.

Key drivers include proactive government policies that aim to reduce healthcare expenditures by promoting generic drug use. Incentives and favorable regulations make generics a cost-effective alternative to branded medications. The escalating healthcare costs further bolster the market in Japan. Key Market Trends: Notable trends include increasing collaborations between domestic and international pharmaceutical companies to enhance generic drug development and distribution. Technological advancements in manufacturing also play a significant role in propelling the market.

Notable trends include increasing collaborations between domestic and international pharmaceutical companies to enhance generic drug development and distribution. Technological advancements in manufacturing also play a significant role in propelling the market. Competitive Landscape: The market features a competitive landscape with detailed analyses of market structure, key player positioning, and strategic initiatives. Comprehensive profiles of leading companies are also included to provide insights into the competitive dynamics.

The market features a competitive landscape with detailed analyses of market structure, key player positioning, and strategic initiatives. Comprehensive profiles of leading companies are also included to provide insights into the competitive dynamics. Challenges and Opportunities: While the market faces challenges such as stringent regulatory requirements, opportunities abound with an aging population and the rising demand for cost-effective medications, which drive market growth.

Key Questions Answered in This Report:

How has the Japan generic drug market performed so far, and how will it perform in the coming years?

What has been the impact of COVID-19 on the Japan generic drug market?

What are the various stages in the value chain of the Japan generic drug market?

What are the key driving factors and challenges in the Japan generic drug market?

What is the structure of the Japan generic drug market, and who are the key players?

What is the competitive structure of the market?

Who are the key players/companies in the Japan generic drug market?

Key Attributes:

Report Attribute Details No. of Pages 118 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $12.3 Billion Forecasted Market Value (USD) by 2033 $22.5 Billion Compound Annual Growth Rate 6.9% Regions Covered Japan
[Source link]: https://www.globenewswire.com/news-release/2025/08/29/3141522/28124/en/Japan-Generic-Drug-Market-Trends-Opportunity-and-Forecast-2025-2033-Favorable-Policies-Rising-Healthcare-Costs-and-Growing-Acceptance-of-Generics-Drive-Expansion.html


[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
We use cookies to improve user experience, and analyze website traffic.

For these reasons, we may share your site usage data with our analytics partners. By clicking "Accept Cookies" you consent to store on your device all the technologies described in our Cookie Policy.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html

================================================================================

